National Cancer Institute (NCI): all 3,554 studies

Page 20 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic LeukemiaActive, not recruitingNCT03701282Phase 3
• IFNL4 Genotype for Predicting Response to Ledipasvir/SofosbuvirWithdrawnNCT03639207
• Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology BranchCompletedNCT03627208
• Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgerySuspendedNCT03604991Phase 2/3
• Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaActive, not recruitingNCT03604978Phase 1/2
• Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast CancerActive, not recruitingNCT03598257Phase 2
• Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT03587311Phase 2
• Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic AstrocytomaActive, not recruitingNCT03528642Phase 1
• Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaActive, not recruitingNCT03502733Phase 1
• Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapyTerminatedNCT03407040
• Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast CancerWithdrawnNCT03377101Phase 2
• Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic ChangesActive, not recruitingNCT03375307Phase 2
• Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder CancerCompletedNCT03327883
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell LymphomaActive, not recruitingNCT03321643Phase 1
• Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT StudyActive, not recruitingNCT03309033
• Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2Active, not recruitingNCT03284385Phase 2
• Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With CirrhosisActive, not recruitingNCT03278925Phase 1
• Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaActive, not recruitingNCT03269669Phase 2
• Internet-Based and Self-Reports in Assessing Diet and Physical Activity Within AARPCompletedNCT03268577
• Rare CNS Tumors Outcomes &RiskCompletedNCT03251989
• Questionnaire Pre-Test StudyCompletedNCT03248635
• Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial CancerActive, not recruitingNCT03244384Phase 3
• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT03237780Phase 2
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal CancerActive, not recruitingNCT03233711Phase 3
• Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaWithdrawnNCT03220009Phase 2
• Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionWithdrawnNCT03217253Phase 1
• NCI UNC Project ESCCTerminatedNCT03206125
• Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid TumorsTerminatedNCT03189108
• Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation CyclophosphamideCompletedNCT03188419
• Gastric Cancer Precursor Lesions (GCPL) StudyCompletedNCT03188406
• 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate CancerActive, not recruitingNCT03181867Phase 2
• Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO StudyActive, not recruitingNCT03180034Phase 4
• Cervix Image Sharing Protocol (CISP)CompletedNCT03179306
• 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate CancerActive, not recruitingNCT03173924Phase 2
• Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaActive, not recruitingNCT03141684Phase 2
• Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010CompletedNCT03111745
• Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)WithdrawnNCT03109301Phase 2
• Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain CancerTerminatedNCT03107780Phase 1
• Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach CancerCompletedNCT03076567
• A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyActive, not recruitingNCT03076554Phase 2
• Long-Term Stability of Oral Microbiome SamplesCompletedNCT03068546
• Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT03041688Phase 1
• Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric CancerCompletedNCT03030404
• Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid TumorsActive, not recruitingNCT03030378Phase 1
• Prospective Evaluation and Molecular Profiling in People With Gastric TumorsCompletedNCT03027427
• Clinical Sequencing of Cancer and Tissue Repository: OncoGenomicsWithdrawnNCT03027401
• Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT StudyActive, not recruitingNCT02997228Phase 3
• Hyperthyroid Follow-Up StudyCompletedNCT02989103
• Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingNCT02978625Phase 2
• Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingNCT02954874Phase 3
• Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by SurgeryActive, not recruitingNCT02923778Phase 2
• Cancer and Other Disease Risks in U.S. Nuclear Medicine TechnologistsCompletedNCT02911155
• Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results DataCompletedNCT02875327
• The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk TradeoffsWithdrawnNCT02874053
• Atezolizumab in Treating Patients With Cancer Following Adoptive Cell TransferActive, not recruitingNCT02862275Phase 1
• Natural History of and Specimen Banking for People With Tumors of the Central Nervous SystemCompletedNCT02851706
• Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast CancerActive, not recruitingNCT02849496Phase 2
• Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary MetastasectomyWithdrawnNCT02839694Phase 1
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• Differential Influences of Integral and Incidental Emotion on Cancer-related Judgments and Decision MakingCompletedNCT02829554
• Collection of Tissue Blocks or Slides From Patients With CancerCompletedNCT02810405
• Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT02791919Phase 1
• Helicobacter Pylori Genome Project (HpGP)TerminatedNCT02788214
• Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell CarcinomaCompletedNCT02775812Phase 1
• DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus InfectionActive, not recruitingNCT02772003Phase 1
• Early Life Exposures in AgricultureCompletedNCT02743481
• Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear TestCompletedNCT02734303
• Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaCompletedNCT02709226Phase 1
• Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer PatientsTerminatedNCT02706652
• Chile Biliary Longitudinal StudyCompletedNCT02692911
• Biomarker Analysis of Central Nervous System TumorsTerminatedNCT02692898
• Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingNCT02669251Phase 1/2
• Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi SarcomaActive, not recruitingNCT02659930Phase 1
• Liposomal Irinotecan and Veliparib in Treating Patients With Solid TumorsCompletedNCT02631733Phase 1
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnNCT02627430Phase 1
• Gut Microbiota in People With Hepatocellular Carcinoma (HCC)WithdrawnNCT02599909
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02595944Phase 3
• M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02595931Phase 1
• Nivolumab in Treating Patients With High-Risk Kidney Cancer Before SurgeryTerminatedNCT02595918Phase 1
• Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in ChinaCompletedNCT02586532
• Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
• Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)TerminatedNCT02566161
• Clinical and Laboratory Analysis of Familial CancerCompletedNCT02565004
• Follow-Up Study of People Treated for ScoliosisCompletedNCT02546479
• Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung CancerCompletedNCT02535325Phase 1
• Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell LymphomaActive, not recruitingNCT02520791Phase 1
• Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT02520778Phase 1
• Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02503722Phase 1
• Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02503709Phase 1
• Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorActive, not recruitingNCT02496663Phase 1
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1
• In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic MelanomaWithdrawnNCT02489266Phase 1
• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...Active, not recruitingNCT02484404Phase 1/2
• Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerTerminatedNCT02474173Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerActive, not recruitingNCT02453620Phase 1
• Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid TumorsCompletedNCT02423057Phase 1
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsCompletedNCT02415153Phase 1

← National Cancer Institute (NCI) overview and focus areas